Technology

KalVista Pharmaceuticals

$16.98
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.41 (-2.36%) Today
$0.00 (0.00%) As of 9:00 PM UTC after-hours

Why Robinhood?

You can buy or sell KALV and other stocks, options, and ETFs commission-free!

About KALV

KalVista Pharmaceuticals, Inc. Common Stock, also called KalVista Pharmaceuticals, is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello and is headquartered in Cambridge, MA. The listed name for KALV is KalVista Pharmaceuticals, Inc. Common Stock.

CEO
T. Andrew Crockett
Employees
56
Headquarters
Cambridge, Massachusetts
Founded
2011
Market Cap
287.49M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
152.54K
High Today
$17.67
Low Today
$16.26
Open Price
$17.67
Volume
147.60K
52 Week High
$20.21
52 Week Low
$5.61

Collections

KALV Earnings

-$0.61
-$0.41
-$0.20
$0.00
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Estimated
— per share
Actual
Expected Mar 10, Pre-Market

You May Also Like

FIZZ
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure